PPT-Improving access to controlled medicines

Gilles Forte Coordinator Policy Access and Use Team Essential Medicines and Health Products WHO mandate within the International Drug Control Conventions 1961 Single Convention on Narcotic Drugs Article 3. Willem Scholten, PharmD, MPA. Team Leader, Access to Controlled Medicines,. World Health Organization, Geneva, Switzerland. TECHNICAL BRIEFING SEMINAR . Geneva, 29 October – 2 November 2012. Overview. –. lessons from HIV. EPIP, 5 September 2017, Bordeaux. . Ellen ‘t Hoen, LLM. University Medical Centre Groningen, Global Health Unit. @. ellenthoen. www.medicineslawandpolicy.org. Brief history. Stops AIDS National Gathering . 1st November 2014. Aliénor Devali. ère. Health. Action International (HAI) Europe. This document arises from HAI Europe’s Operating Grant 2014, which has received funding from the . Some New Development. I P C Meeting, Copenhagen (through VC). Zafar Mirza. 18 June 2015, Brussels. . WHO/EC Project:. . “. Improving access to medical products in developing countries through building capacity for local production and related technology transfer”. Willem Scholten, PharmD, MPA. Team Leader, Access to Controlled Medicines,. World Health Organization, Geneva, Switzerland. TECHNICAL BRIEFING SEMINAR . Geneva, 29 October – 2 November 2012. Overview. WHO EMP and NVI Departments. Access to NCD essential medicines . on the global agenda. Access to chronic disease medicines is required for the fulfilment of MDG8. Governments, in collaboration with the private sector, should give greater priority to treating chronic diseases and improving the accessibility of medicines to treat them (MDG Report 2009). sustainably and equitably financed. Summary Discussion…1. What information needed to estimate cost program of medicines benefits. MBM . Ned to estimate the total economic cost of setting up a MBM program. Some New Development. I P C Meeting, Copenhagen (through VC). Zafar Mirza. 18 June 2015, Brussels. . WHO/EC Project:. . “. Improving access to medical products in developing countries through building capacity for local production and related technology transfer”. Draft concept for a new World Bank-led multi-stakeholder initiative . August 2014, Andreas . Seiter. What is AIM 2030?. An initiative to maximize access to innovative medicines for priority diseases in low- and middle income countries (LMICs). Some New Development. I P C Meeting, Copenhagen (through VC). Zafar Mirza. 18 June 2015, Brussels. . WHO/EC Project:. . “. Improving access to medical products in developing countries through building capacity for local production and related technology transfer”. Willem Scholten, PharmD, MPA. Team Leader, Access to Controlled Medicines,. World Health Organization, Geneva, Switzerland. TECHNICAL BRIEFING SEMINAR . Geneva, 29 October – 2 November 2012. Overview. Dr Cécile . Macé. . WHO EMP , Mr Arne-Petter . Sanne. WHO MND, . Mr . Ajuebor. Onyema WHO MND. NCD Programme Managers Seminar. 4 June 2014. Access to NCD essential medicines . on the global agenda. Case Management. George Jagoe . EVP, Access & Product Management, MMV. . . The access team at MMV is heavily focused on the needs of control today. 4. Achieving patient impact means addressing many hurdles to access. Basic enquiry answering. September . 2016. Session aims. Increase awareness of the Medicines Information (MI) services. UK. Wales. Increase awareness of the questions to ask an enquirer. Have practical experience using some resources which will be...